April 29, 2020 / 1:39 PM / a month ago

BRIEF-New Capricor Data Reports 100% Survival In Critical Covid-19 Patients Treated With Cap-1002

April 29 (Reuters) - Capricor Therapeutics Inc:

* NEW CAPRICOR DATA REPORTS 100 PERCENT SURVIVAL IN CRITICAL COVID-19 PATIENTS TREATED WITH CAP-1002

* CAPRICOR THERAPEUTICS INC - OF SIX CRITICALLY ILL COVID-19 PATIENTS TREATED WITH CAP-1002, FOUR OF THEM HAVE BEEN DISCHARGED

* CAPRICOR THERAPEUTICS INC - FDA APPROVED EXPANDED ACCESS PROTOCOL TO TREAT UP TO 20 ADDITIONAL COVID-19 PATIENTS WITH CAP-1002

* CAPRICOR - IN 1 MONTH, 6 CRITICALLY ILL COVID-19 PATIENTS, ALL SUFFERING FROM ARDS, 5 OF WHOM WERE ON MECHANICAL VENTILATORY SUPPORT SAFELY TREATED WITH CAP-1002

* CAPRICOR - IN COMPASSIONATE CARE CASES, 6 COVID-19 PATIENTS RECEIVED IV INFUSIONS OF 150 MILLION ALLOGENEIC CARDIOSPHERE-DERIVED CELLS (CAP-1002)

* CAPRICOR THERAPEUTICS - NO ADVERSE EVENTS RELATED TO ADMINISTRATION OF CAP-1002 WERE OBSERVED IN COVID-19 PATIENTS

* CAPRICOR- 4 OF 6 PATIENTS NO LONGER REQUIRED VENTILATOR SUPPORT WITHIN JUST 1-4 DAYS AFTER INFUSION OF 150 MILLION ALLOGENEIC CARDIOSPHERE-DERIVED CELLS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below